rituximab

rituximab is a chimeric monoclonal antibody medication primarily used in the treatment of certain autoimmune diseases and hematologic cancers. It was one of the first monoclonal antibodies approved for use in oncology by the FDA. The drug works by targeting the CD20 antigen found on the surface of B cells, leading to their depletion from the bloodstream.

Medical uses

rituximab is indicated for the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma, often in combination with chemotherapy regimens like CHOP. It is also approved for use in chronic lymphocytic leukemia. In autoimmune disorders, it is used for conditions such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis, typically after failure of other agents like TNF inhibitors. The medication is administered via intravenous infusion in a clinical setting, with dosing schedules varying by indication and protocol.

Mechanism of action

The primary mechanism involves binding with high affinity to the CD20 antigen, a protein expressed on the surface of pre-B and mature B cells but not on plasma cells or stem cells. This binding can initiate several immune-mediated actions, including complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which recruit components of the immune system like natural killer cells. Additionally, engagement of the antibody can induce direct apoptosis, or programmed cell death, within the targeted B cells. The depletion of these cells is a central therapeutic effect in both malignant and autoimmune contexts.

Adverse effects

Common adverse reactions include infusion reactions, which can feature fever, chills, and hypotension, particularly during the first administration. Significant risks include severe mucocutaneous reactions, such as those described in Stevens–Johnson syndrome, and progressive multifocal leukoencephalopathy, a rare and often fatal viral infection of the brain caused by the JC virus. Other serious effects can involve hepatitis B virus reactivation, cardiac arrhythmia, and bowel obstruction. Premedication with agents like acetaminophen, antihistamines, and glucocorticoids is standard to mitigate infusion-related symptoms.

History

The development of rituximab originated from research at IDEC Pharmaceuticals, with key collaborative work involving Ronald Levy at Stanford University. The drug represented a significant advance in the field of immunotherapy, being the first monoclonal antibody approved for cancer treatment in the United States, receiving FDA approval for non-Hodgkin lymphoma in 1997. Its success paved the way for numerous other biologic therapies and established the commercial viability of monoclonal antibodies, influencing companies like Genentech and Biogen Idec. Subsequent clinical trials expanded its use into autoimmune diseases, leading to approvals for rheumatoid arthritis in 2006.

Society and culture

rituximab is marketed under the trade names Rituxan in the United States and MabThera in many other countries, with Roche and Biogen being major stakeholders in its distribution. Its high cost has been a subject of discussion within healthcare systems like the National Health Service in the United Kingdom. The drug has been included on the WHO Model List of Essential Medicines, recognizing its importance in a global health context. Its development story is frequently cited in narratives about the growth of the biotechnology industry in the late 20th century.

Category:Monoclonal antibodies Category:Antineoplastic drugs Category:Immunosuppressive drugs